Paper Details
- Home
- Paper Details
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Author: AlizadehHussain, DemeterJudit, HardiApor, IllésÁrpád, KosztolányiSzabolcs, MassziTamás, MikalaGábor, NagyZsolt, PlanderMárk, SchneiderTamás, VargaGergely, VáróczyLászló
Original Abstract of the Article :
Összefoglaló. Bevezetés: A myeloma multiplex mindmáig alapvetően gyógyíthatatlan betegség, ezért nagy klinikai jelentőségük van az eredményes mentő kezeléseknek. A szájon át adható első proteaszómagátlóval, az ixazomibbal kiegészített lenalidomid-dexametazon terápia jól tolerálható, csak orális szer...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1556/650.2021.32179
データ提供：米国国立医学図書館（NLM）
Ixazomib-Lenalidomide-Dexamethasone: A Long-Term Solution for Multiple Myeloma
This study investigates the effectiveness of a triple-drug regimen, consisting of [ixazomib, lenalidomide, and dexamethasone], in treating relapsed and refractory multiple myeloma. The authors present a retrospective analysis of 80 patients who received this treatment, focusing on long-term progression-free survival. This study highlights the potential of this triple-drug regimen to provide long-term disease control in multiple myeloma patients, offering hope for improved outcomes and potentially extended life expectancy.
Ixazomib-Lenalidomide-Dexamethasone: A Promising Treatment for Refractory Multiple Myeloma
The study reveals the potential of a triple-drug regimen, consisting of ixazomib, lenalidomide, and dexamethasone, to provide long-term disease control in multiple myeloma patients. The researchers found that a significant proportion of patients experienced a response to treatment, with some achieving progression-free survival for over two years. This finding offers hope for improved outcomes and potentially extended life expectancy for patients with relapsed and refractory multiple myeloma. The study encourages continued research into the long-term efficacy and safety of this triple-drug regimen, seeking to optimize treatment strategies and improve patient outcomes.
Understanding the Implications for Multiple Myeloma Treatment
The study underscores the importance of developing effective and safe treatment options for multiple myeloma, a complex and often challenging cancer to manage. The findings highlight the potential of a triple-drug regimen, consisting of ixazomib, lenalidomide, and dexamethasone, to provide long-term disease control in patients with relapsed and refractory disease. This research encourages further research into the long-term efficacy and safety of this regimen, seeking to optimize treatment strategies and improve patient outcomes.
Dr.Camel's Conclusion
This research offers a glimmer of hope in the vast desert of multiple myeloma treatment, where challenges abound. The study's findings suggest that this triple-drug regimen may offer a promising path towards long-term disease control and potentially extended life expectancy for patients with relapsed and refractory disease. This research encourages continued exploration of this regimen's potential, seeking to optimize treatment strategies and improve patient outcomes.
Date :
- Date Completed 2021-09-07
- Date Revised 2022-05-31
Further Info :
Related Literature
Hungarian
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.